LYON, November 18, 2026 — A new analysis of 54 countries shows that overall cancer mortality fell below expected levels during the first four years of the COVID-19 pandemic, but the gap widened over time for cancers that are usually treatable. The study, led by the International Agency for Research on Cancer (IARC) and the World Health Organization (WHO), found that disruptions to screening and treatment drove excess deaths in breast cancer and leukaemia, while mortality for aggressive cancers such as lung and pancreatic cancer tracked closely with pre-pandemic trends.
Overall Mortality Fell But Gaps Widened
Researchers examined data from the WHO Mortality Database covering 2020 through 2023 and compared observed death rates against expected rates calculated from 2015 to 2019. In the first pandemic year, all-cancer mortality was often lower than projected. However, the discrepancies between observed and expected rates gradually increased in 2021, 2022, and 2023, suggesting that the indirect effects of the crisis accumulated over time.
The study, published in the International Journal of Cancer, analyzed mortality for all cancers combined and for four specific types: lung, pancreatic, breast cancer, and leukaemia. The analysis was stratified by age group, cancer type, and country.
Prognosis Shaped the Pandemic Effect
For cancers with generally poor prognosis, including lung and pancreatic cancer, observed mortality rates remained close to expected rates across regions and age groups. The researchers note that because outcomes for these cancers are less improved by medical interventions, health-service disruptions had a smaller measurable impact on mortality.
In contrast, for cancers with generally more favourable prognosis — specifically breast cancer and leukaemia — observed mortality rates showed greater deviations from expected rates. The encouraging part is that these are cancers where timely screening and treatment usually save lives. The findings suggest that for treatable cancers, health-service disruptions during crises have particularly detrimental effects.
Clearing Backlogs Before the Next Crisis
The authors argue that recovery strategies must systematically address screening and treatment backlogs. They define resilient health systems as those in which healthcare actors, institutions, and populations can prepare for, respond to, and adapt to crises while maintaining essential functions. Given the inevitability of future pandemics and other crises, the study calls for an urgent need to build systems capable of sustaining cancer care without major or prolonged disruptions.
Early findings suggest that the pandemic’s legacy on cancer mortality is not uniform; it falls hardest where care delays interrupt a curable trajectory. Patients should talk to their doctor about any delayed screenings or symptoms they may have put off during the pandemic years.
Sources
- COVID-19 pandemic
- Health workers receiving more threats since COVID-19 outbreak, study says
- Review Highlights COVID-19 Impact on Vulnerable Youth | Neuro Therapy Today
- Regulator raised concerns with Swinburne’s pitch for re-registration
- Global Evaluation Assesses How Field Epidemiology Graduates Apply
- Global impact of the COVID-19 pandemic on cancer mortality: an analysis of 54 countries
Photo: Rystheguy (CC BY-SA 3.0)





